TY  - GEN
AB  - Cancer treatment has advanced rapidly in the past decade, with checkpoint inhibitors (CPIs) delivering improved outcomes across a variety of malignant indications. However, their application is associated with the development of immune-related adverse events (irAEs), which are linked to the physiological role of checkpoint molecules like PD-1 and CTLA-4 in regulating immunological self-tolerance and safeguarding non-malignant tissues from the immune response. CPIs disrupt these checkpoints, restoring the immune system's cytotoxic function to recognize and eliminate cancer cells, potentially leading to immune dysregulation and the onset of irAEs.
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AU  - Billo, Avery
AU  - Hornick, Noah
AU  - Fey, Rosalyn M.
DA  - 2024
DO  - 10.6083/bpxhc43566
DO  - doi
ID  - 43566
KW  - Dermatology
KW  - Melanoma
KW  - Neoadjuvant Therapy
KW  - transcriptomics
KW  - immune-related adverse reaction
L1  - https://digitalcollections.ohsu.edu/record/43566/files/ResearchWeek.2024.Billo.Avery.pdf
L2  - https://digitalcollections.ohsu.edu/record/43566/files/ResearchWeek.2024.Billo.Avery.pdf
L4  - https://digitalcollections.ohsu.edu/record/43566/files/ResearchWeek.2024.Billo.Avery.pdf
LA  - eng
LK  - https://digitalcollections.ohsu.edu/record/43566/files/ResearchWeek.2024.Billo.Avery.pdf
N2  - Cancer treatment has advanced rapidly in the past decade, with checkpoint inhibitors (CPIs) delivering improved outcomes across a variety of malignant indications. However, their application is associated with the development of immune-related adverse events (irAEs), which are linked to the physiological role of checkpoint molecules like PD-1 and CTLA-4 in regulating immunological self-tolerance and safeguarding non-malignant tissues from the immune response. CPIs disrupt these checkpoints, restoring the immune system's cytotoxic function to recognize and eliminate cancer cells, potentially leading to immune dysregulation and the onset of irAEs.
PB  - Oregon Health and Science University
PY  - 2024
T1  - Distinct inflammatory mechanisms underlie lichen planus and lichenoid reactions to checkpoint inhibition
TI  - Distinct inflammatory mechanisms underlie lichen planus and lichenoid reactions to checkpoint inhibition
UR  - https://digitalcollections.ohsu.edu/record/43566/files/ResearchWeek.2024.Billo.Avery.pdf
Y1  - 2024
ER  -